key: cord-0842503-jaedugd2 authors: Li, Yang; Hou, Hongjie; Diao, Jie; Wang, Yadong; Yang, Haiyan title: Neutrophil‐to‐lymphocyte ratio is independently associated with COVID‐19 severity: An updated meta‐analysis based on adjusted effect estimates date: 2021-01-27 journal: Int J Lab Hematol DOI: 10.1111/ijlh.13475 sha: 3c43f0444a681e82bbd851747865bebc9371ea59 doc_id: 842503 cord_uid: jaedugd2 nan As the current epidemic caused by coronavirus disease 2019 (COVID-19) progresses, prognostic markers that might be associated with adverse outcomes of COVID-19 patients caught the researchers' attention. Neutrophil-to-lymphocyte ratio (NLR) is an easily accessible value that has been known to correlate with inflammation and prognosis in several conditions. Recently, a meta-analysis by were based on unadjusted effect estimates. Two other meta-analyses on this topic also reported unadjusted effect estimates. 2, 3 It was worth noting that a univariate analysis indicated that NLR was an important risk factor significantly associated with COVID-19 severity. However, inconsistent conclusions were drawn from a multivariate analysis. [4] [5] [6] For example, in the article of Zhang et al, 4 univariate analysis showed that NLR was a risk factor for the disease severity of COVID-19 (odds ratio (OR) = 1.55, 95% CI: 1.18-2.03), while multivariate analysis demonstrated that NLR was not significantly associated with COVID-19 severity (OR = 1.17, 95% CI: 0.85-1.60). Similarly, Wang et al 5 reported that NLR was significantly associated with COVID-19 severity in univariate analysis (OR = 1.44, 95% CI: 1.23-1.68), but this significant association disappeared in a multivariate analysis (OR = 0.99, 95% CI: 0.97-1.01). Similar findings were also observed in Wang et al's study. 6 This meant that various factors such as age, gender, and other confounders (such as diabetes, hypertension, cerebrovascular diseases, and chronic obstructive pulmonary disease, etc.) 7-11 might affect the association between NLR and COVID-19 severity. So, an updated meta-analysis based on published studies reporting adjusted effect estimates is needed to clarify the association between NLR and COVID-19 severity. This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalyses (PRISMA) guidelines. We carried out an electronic search in PubMed, Web of Science, and EMBASE until October 23, 2020. The following keywords were used: (("COVID-19" or "2019-nCoV" or "SARS-CoV-2" or "coronavirus disease 2019") and ("NLR" or "neutrophil-to-lymphocyte ratio" or "neutrophil/lymphocyte") and ("clinical progression" or "mortality" or "severity")). Articles that reported the relationship between NLR and COVID-19 severity (including severe, critical, or mortal outcomes) using multivariate analysis model were selected. Reviews, erratum, duplicated papers, comments, and articles reporting the relationship between NLR and COVID-19 severity using univariate analysis model were excluded. Heterogeneity was evaluated by I 2 statistic. The combined effect with 95% CI was estimated by fixed-effects model (I 2 < 50% in heterogeneity test) or random-effects model (I 2 > 50% in heterogeneity test). We used Begg's test and Egger's test to assess publication bias, and sensitivity analysis to evaluate the stability of our results. Subgroup analyses by effect estimate, study design, sample size, country, and age were also performed. We estimated the mean and standard deviation according to Wan et al 12 when sample size, median, and interquartile range (IQR) were provided. We used STATA 11.2 to conduct all calculations, and P < .05 was considered significant. The flow diagram of study selection is shown in Figure S1 , and the PRISMA checklist is shown in Table S1 . Initially, 530 articles were identified. After carefully reading titles, abstracts, and full texts, 496 articles were excluded. Finally, 34 studies with 25 074 COVID-19 patients were included. The main characteristics of the included studies are shown in Table 1 . We observed that there was a significant association between elevated NLR and an increased risk for COVID-19 severity on the basis of adjusted effect estimates (pooled effect = 1.12, 95% CI: 1.08-1.16; I 2 = 86.0%, P < .001; random-effects model; Figure 1A ). When the disease outcomes were restricted to death, the significant association between NLR and death among COVID-19 patients still existed (pooled effect = 1.11, 95% CI: 1.06-1.17; Figure 1B Abbreviations: A, ambispective study; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; AFR, albumin-to-fibrinogen ratio; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMC, absolute monocyte count; aPTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; BUN/Cr ratio, blood urea nitrogen/creatinine ratio; CI, confidence interval; CK, creatinine kinase; CKD, chronic kidney disease; CK-MB, creatine kinase isoenzyme-MB; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CRPR, ratio of C-reactive protein (the ratio of CRP value/upper limit of the CRP value); CVD, cardiovascular disease; DM, diabetes mellitus; dNLR, derived neutrophil-lymphocyte ratio; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; FIB, fibrinogen content; GFR, glomerular filtration rate; GLU, fasting blood glucose; HF, heart failure; HR, hazard ratio; HsCAR, high-sensitivity C-reactive protein-albumin ratio; HsCPAR, high-sensitivity C-reactive protein-prealbumin ratio; HTN, hypertension; IL-6, interleukin-6; INR, international normalized ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; LYM%, lymphocyte percentage; MLR, monocyte-tolymphocyte ratio; NEU%, neutrophil percentage; NLR, neutrophil-to-lymphocyte ratio; NR, not reported; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; OR, odds ratio; P, prospective study; PCT, procalcitonin; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; PT, prothrombin time; R, retrospective study; SaO 2 , arterial oxygen saturation; Scr, serum creatinine; SII, systemic immune-inflammation index; SOFA, sequential organ failure assessment; T2DM, type 2 diabetes mellitus; TBIL, total bilirubin; WBC, white blood cell count. F I G U R E 1 (A) Forest plot of the association between elevated NLR and an increased risk for COVID-19 severity; (B) forest plot of the association between NLR and death among COVID-19 patients when the disease outcomes were restricted to death. * indicates combined effects based on subgroups association between NLR and COVID-19 severity was observed in retrospective studies (pooled effect = 1.13, 95% CI: Figure S6 ). Sensitivity analysis indicated that our results were reliable and robust ( Figure S7 ). Publication bias was found in Egger's test (P < .001; Figure S8A ), but not in Begg's test (P = .906; Figure S8B ). In summary, our findings demonstrated that elevated NLR was an independent risk factor associated with COVID-19 severity. Therefore, patients with elevated NLR should be given more attention to prevent further deterioration of the disease or even death. COVID-19, death, meta-analysis, NLR, severity We would like to thank Timothy Bonney Oppong for his kind help in editing the English language of our manuscript. We also thank Li Shi, Ying Wang, Jie Xu, Xuan Liang, Wenwei Xiao, Peihua Zhang, and Jian Wu for their kind help in collecting data and valuable suggestions for analyzing data. All authors report that they have no potential conflict of interest. All data relevant to this study are included in this article or uploaded as supplementary information. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19 Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis A novel scoring system for prediction of disease severity in COVID-19 The timeline and risk factors of clinical progression of COVID-19 in Shenzhen The Prognostic Nutritional Index is associated with mortality of COVID-19 patients in Wuhan Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis The association of hypertension with the severity and mortality of COVID-19 patients: evidence based on adjusted effect estimates The association of diabetes with COVID-19 disease severity: evidence from adjusted effect estimates The Association of Cerebrovascular Disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range